BACKGROUND & AIMS: High-density lipoproteins (HDLs) protect against atherosclerotic cardiovascular disease, mainly by promoting reverse cholesterol transport (RCT). Biliary sterol secretion supposedly represents the final step in RCT, but the relevance of this pathway has not been explored. We tested the dependency of RCT on functional biliary sterol secretion. METHODS: Macrophage-to-feces RCT was studied in mice with abolished (bile duct ligation) or decreased biliary sterol secretion (adenosine triphosphate binding cassette transporter B4 (Abcb4)-/- mice, with and without administration of a liver X receptor [LXR] agonist) after intraperitoneal injection of (3)H-cholesterol-loaded primary macrophage foam cells from mice. Fecal tracer excretion and also fecal mass sterol excretion were measured. Metabolism and tissue uptake of HDL cholesteryl ester was assessed with HDL kinetic studies. RESULTS: Bile-duct ligation completely abolished RCT from (3)H-cholesterol-loaded macrophages to feces (P < .001). In Abcb4-/- mice lacking biliary cholesterol secretion, RCT was decreased markedly; fecal (3)H-tracer excretion was almost absent within neutral sterols (P < .001) and reduced within bile acids (P < .05). LXR activation stimulated RCT in wild-type (5.5-fold; P < .001) but not Abcb4-/- mice, whereas mass fecal sterol excretion increased similarly in both models (P < .05). Kinetic studies revealed minimal uptake of HDL cholesteryl ester by the intestine, which decreased on LXR activation (P < .05). CONCLUSIONS: Functional RCT depends on biliary sterol secretion; there is no compensatory increase in RCT via bile acids. The stimulating effect of LXR agonists on RCT requires biliary cholesterol secretion. These results have implications for therapies against atherosclerotic cardiovascular disease targeting the RCT pathway.
BACKGROUND & AIMS: High-density lipoproteins (HDLs) protect against atherosclerotic cardiovascular disease, mainly by promoting reverse cholesterol transport (RCT). Biliary sterol secretion supposedly represents the final step in RCT, but the relevance of this pathway has not been explored. We tested the dependency of RCT on functional biliary sterol secretion. METHODS: Macrophage-to-feces RCT was studied in mice with abolished (bile duct ligation) or decreased biliary sterol secretion (adenosine triphosphate binding cassette transporter B4 (Abcb4)-/- mice, with and without administration of a liver X receptor [LXR] agonist) after intraperitoneal injection of (3)H-cholesterol-loaded primary macrophage foam cells from mice. Fecal tracer excretion and also fecal mass sterol excretion were measured. Metabolism and tissue uptake of HDL cholesteryl ester was assessed with HDL kinetic studies. RESULTS: Bile-duct ligation completely abolished RCT from (3)H-cholesterol-loaded macrophages to feces (P < .001). In Abcb4-/- mice lacking biliary cholesterol secretion, RCT was decreased markedly; fecal (3)H-tracer excretion was almost absent within neutral sterols (P < .001) and reduced within bile acids (P < .05). LXR activation stimulated RCT in wild-type (5.5-fold; P < .001) but not Abcb4-/- mice, whereas mass fecal sterol excretion increased similarly in both models (P < .05). Kinetic studies revealed minimal uptake of HDL cholesteryl ester by the intestine, which decreased on LXR activation (P < .05). CONCLUSIONS: Functional RCT depends on biliary sterol secretion; there is no compensatory increase in RCT via bile acids. The stimulating effect of LXR agonists on RCT requires biliary cholesterol secretion. These results have implications for therapies against atherosclerotic cardiovascular disease targeting the RCT pathway.
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Robin P F Dullaart; Jan-Stephan F Sanders; Stephan J L Bakker; Uwe J F Tietge Journal: J Am Soc Nephrol Date: 2015-08-28 Impact factor: 10.121
Authors: Carlos L J Vrins; Roelof Ottenhoff; Karin van den Oever; Dirk R de Waart; J Kar Kruyt; Ying Zhao; Theo J C van Berkel; Louis M Havekes; Johannes M Aerts; Miranda van Eck; Patrick C N Rensen; Albert K Groen Journal: J Lipid Res Date: 2012-07-16 Impact factor: 5.922
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Thomas Gautier; Patrick C N Rensen; Daniel J Rader; Uwe J F Tietge Journal: J Lipid Res Date: 2012-03-01 Impact factor: 5.922
Authors: David Meriwether; Dawoud Sulaiman; Alan Wagner; Victor Grijalva; Izumi Kaji; Kevin J Williams; Liqing Yu; Spencer Fogelman; Carmen Volpe; Steven J Bensinger; G M Anantharamaiah; Ishaiahu Shechter; Alan M Fogelman; Srinivasa T Reddy Journal: J Lipid Res Date: 2016-05-19 Impact factor: 5.922